Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat.com Is Abbott's January Pullback a Good Time to Buy? Reported by Thomas Hughes. Article Posted: 1/24/2026. 
What You Need to Know - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 pullback has made the stock look attractively valued. The decline—driven more by market angst than by company weakness—appears to be a knee-jerk overreaction that has pushed the shares back into a buy zone. 
The former CEO of Google calls it the most important thing to happen in 500, maybe 1,000 years of human society. A former U.S. Treasury Secretary says when your great-grandchildren write the history of this period, the political headlines will be the second or third story. The first story is something none of us have seen before. The dot-com collapse, global financial crisis, and COVID-19 pandemic don't compare to what's coming next. We may be entering a period of dramatic, almost unimaginable change. See the full warning and how to prepare now. The zone aligns with market action from 2022 to 2024, when Abbott was recovering from its post-COVID-19 revenue contraction and institutions actively accumulated the stock. Abbott Laboratories Growth Accelerates The most that can be criticized about Abbott Laboratories' Q4 results and guidance is that some metrics missed market expectations. Still, revenue of $11.46 billion was up 4.5% year over year, margins improved, and adjusted earnings accelerated. Revenue growth missed by several hundred basis points, but margin strength helped offset that, with adjusted earnings per share (EPS) rising about 12%—slightly ahead of consensus. By segment, the results highlighted the strength of Abbott's diversified healthcare portfolio. The Nutrition and Diagnostics segments contracted—Nutrition fell nearly 9%—but solid growth in Established Pharmaceuticals and MedTech more than offset those declines. The pharmaceutical segment grew about 9%, driven by generics and emerging markets, while MedTech rose roughly 12.3%, with strength across its sub-segments. Margins improved as well, though they came in short of some analyst forecasts. A product-mix shift, strength in MedTech, reduced COVID-19 sales and operational improvements combined to lift margins above expectations. Looking forward, management expects earnings to grow another ~10% in 2026, outpacing revenue growth and supporting the company's capital-return plans. Abbott's capital returns are a key part of the investment case. The company is a Dividend King, having raised its payout annually for more than 50 years, and appears positioned to continue doing so. After the pullback the yield is about 2.5%, and Abbott is expected to pay out less than half of consensus earnings, leaving room for share buybacks—another important mechanism that helps offset dilutive share-based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts noted the revenue miss, but no major rating or price-target changes were issued the morning of the release. The prevailing view is that this is a fundamentally healthy company that can continue returning capital while reinvesting in growth. MarketBeat's consensus price target implies up to roughly 30% upside, potentially lifting the shares to new all-time highs; even low-end targets suggest some upside potential. Key catalysts include the expanding MedTech portfolio, AI integration across operations and products, margin expansion and strategic acquisitions. The acquisition of Exact Sciences is one example of how Abbott is broadening its revenue and profit streams and strengthening its product pipeline. The recent decline has been steep and could deepen, but institutions that accumulated shares throughout 2025 are likely buyers at these discounted levels. Early technical support appears around the $105 to $110 range, although that level is not yet confirmed. The downside risk is that ABT shares may test the low end of the buy zone before a rebound, potentially dipping toward the $95 area or lower.
| 
